Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention

被引：80

作者：

Garcia-Vidal, C. ^{[1
,2
]}

Rodriguez-Fernandez, S. ^{[2
]}

Teijon, S. ^{[2
]}

Esteve, M. ^{[3
]}

Rodriguez-Carballeira, M. ^{[2
]}

Lacasa, J. M. ^{[2
]}

Salvador, G. ^{[4
]}

Garau, J. ^{[2
]}

机构：

[1] Hosp Univ Bellvitge, Infect Dis Serv, Barcelona 08907, Spain

[2] Univ Barcelona, Hosp Mutua Terrassa, Serv Internal Med, Barcelona, Spain

[3] Univ Barcelona, Hosp Mutua Terrassa, Serv Gastroenterol, Barcelona, Spain

[4] Univ Barcelona, Hosp Mutua Terrassa, Serv Rheumatol, Barcelona, Spain

来源：

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES | 2009年 / 28卷 / 04期

关键词：

TUBERCULIN SKIN-TEST; NECROSIS-FACTOR ANTAGONISTS; FACTOR-ALPHA ANTAGONISTS; GAMMA RELEASE ASSAYS; RHEUMATOID-ARTHRITIS; LATENT TUBERCULOSIS; HEPATITIS-B; THERAPY; METHOTREXATE; REACTIVATION;

D O I：

10.1007/s10096-008-0628-x

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

We sought to determine factors associated with opportunistic infections (OI) in infliximab-treated patients. A retrospective study cohort (1999-2004) was examined. Nine OI were diagnosed in 94 infliximab-treated patients: tuberculosis (four), visceral leishmaniasis (one), pyogenic muscular abscess (one Salmonella spp. and one Streptococcus pneumoniae), and two viral infections (hepatitis B virus [HBV] and zoster ophthalmicus). The risk for OI was significantly higher in the first year of treatment (odds ratio [OR] 8; 95% confidence interval [CI] 2-50). Previous treatment with more than two immunosuppressive drugs was the only factor related to OI (OR 8.686; 95% CI 1.889-39.943). We identified the subset of patients treated with infliximab who had a higher risk for OI. The screening of latent infections is key to diminishing the incidence of these infections.

引用

页码：331 / 337

页数：7

共 50 条

[31] Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib [J].

Holowka, Thomas ;

Cheung, Harry ;

Malinis, Maricar ;

Gan, Geliang ;

Deng, Yanhong ;

Perreault, Sarah ;

Isufi, Iris ;

Azar, Marwan M. .

JOURNAL OF INFECTION AND CHEMOTHERAPY, 2021, 27 (12) :1700-1705

[32] Identification of risk factors for failure in patients with skin and soft tissue infections [J].

Cieri, Brittany ;

Conway, Erin L. ;

Sellick, John A. ;

Mergenhagen, Kari A. .

AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2019, 37 (01) :48-52

[33] Risk factors of septic shock in patients with hematologic malignancies and Pseudomonas infections [J].

Jeddi, Ramzi ;

Ghedira, Hela ;

Ben Amor, Ramzi ;

Turki, Amel ;

Kacem, Karima ;

Ben Abdennebi, Yosr ;

Ben Lakhal, Raihane ;

Aissaoui, Lamia ;

Ben Abid, Hela ;

Hadjali, Zaher Bel ;

Meddeb, Balkis .

HEMATOLOGY, 2011, 16 (03) :160-165

[34] Readmission Rates in Stroke Patients with and without Infections: Incidence and Risk Factors [J].

Boehme, Amelia K. ;

Oka, Maitreyi ;

Cohen, Bevin ;

Elkind, Mitchell S. V. ;

Larson, Elaine ;

Mathema, Barun .

JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2022, 31 (01)

[35] Bloodstream infections in cancer patients. Risk factors associated with mortality [J].

Islas-Munoz, Beda ;

Volkow-Fernandez, Patricia ;

Ibanes-Gutierrez, Cynthia ;

Villamar-Ramirez, Alberto ;

Vilar-Compte, Diana ;

Cornejo-Juarez, Patricia .

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2018, 71 :59-64

[36] Infections in Hospitalised Patients with Multiple Myeloma: Main Characteristics and Risk Factors [J].

Valkovic, Toni ;

Gacic, Vedrana ;

Ivandic, Jelena ;

Petrov, Bozo ;

Dobrila-Dintinjana, Renata ;

Dadic-Hero, Elizabeta ;

Nacinovic-Duletic, Antica .

TURKISH JOURNAL OF HEMATOLOGY, 2015, 32 (03) :234-242

[37] Risk of serious infections in arthritis patients treated with biological drugs: a matched cohort study and development of prediction model [J].

Krabbe, Simon ;

Gron, Kathrine L. ;

Glintborg, Bente ;

Norgaard, Mette ;

Mehnert, Frank ;

Jarbol, Dorte E. ;

Ostergaard, Mikkel ;

Hetland, Merete L. .

RHEUMATOLOGY, 2021, 60 (08) :3834-3844

[38] Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease [J].

Steenholdt, C. ;

Svenson, M. ;

Bendtzen, K. ;

Thomsen, O. O. ;

Brynskov, J. ;

Ainsworth, M. A. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (01) :51-58

[39] Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials [J].

Campbell, Laura ;

Chen, Chen ;

Bhagat, Shweta S. ;

Parker, Richard A. ;

Oestoer, Andrew J. K. .

RHEUMATOLOGY, 2011, 50 (03) :552-562

[40] Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors Japanese Primary Prevention Project [J].

Uchiyama, Shinichiro ;

Ishizuka, Naoki ;

Shimada, Kazuyuki ;

Teramoto, Tamio ;

Yamazaki, Tsutomu ;

Oikawa, Shinichi ;

Sugawara, Masahiro ;

Ando, Katsuyuki ;

Murata, Mitsuru ;

Yokoyama, Kenji ;

Minematsu, Kazuo ;

Matsumoto, Masayasu ;

Ikeda, Yasuo .

STROKE, 2016, 47 (06) :1605-U468

← 1 2 3 4 5 →